Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

GBM antigens and alloantigens immunotherapeutic vaccine

An orally bioavailable, immunotherapeutic vaccine composed of hydrolyzed and formulated glioblastoma multiforme (GBM) antigens and alloantigens derived from a pool of patients’ cancer cells in the blood and samples of tumor tissues, with potential immunomodulating and antineoplastic activities. Upon oral administration of the GBM antigens and alloantigens immunotherapeutic vaccine, the GBM antigens and alloantigens may stimulate the host immune system via antigen-presenting cells (APCs) lining the gut to mount an immune response against tumor cells expressing these antigens. This may lead to tumor cell death.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:V-Boost
V-Boost Immunitor
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search